The document from the World Health Organization (WHO) titled “Second meeting of the International Health Regulations (2005) Emergency Committee regarding the upsurge of mpox – 2024” provides an important update on the global response to the mpox outbreak. It outlines several key initiatives and recommendations designed to enhance access to innovative healthcare products for mpox. The focus on mpox is crucial given its rapid spread and impact on public health.
The WHO Director-General declared the mpox outbreak a Public Health Emergency of International Concern (PHEIC) due to its fast transmission, particularly in the Democratic Republic of the Congo (DRC) and neighboring regions, along with the emergence of a new sexually transmissible strain of the monkeypox virus.
The WHO Director-General initiated the Emergency Use Listing (EUL) process for mpox vaccines. This action is designed to expedite vaccine access for lower-income countries lacking national regulatory approval.
WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) recommends two vaccines currently used for mpox. WHO-listed national regulatory authorities and individual countries, including Nigeria and the DRC, have approved these vaccines.
WHO is intensifying efforts through coordinated international action to assist countries in ending the outbreaks. This approach involves close collaboration with communities and governments, where country teams work on the frontlines to strengthen measures against mpox.
The Director-General, upon the IHR Emergency Committee’s advice, will issue temporary recommendations to countries. These recommendations aim to boost preparedness, surveillance, and response capabilities for the mpox outbreak.
WHO demonstrates its commitment to ensuring equitable access to essential healthcare products, including diagnostics and treatments, for the impacted countries through its emphasis on a coordinated international response, even though the document does not explicitly detail new initiatives for diagnostic tools and treatments.
The WHO’s response to the mpox outbreak includes initiatives aimed at enhancing access to innovative healthcare products, particularly vaccines. These initiatives focus on emergency use listings, international coordination, and tailored recommendations to support lower-income countries in obtaining these critical healthcare products. Access to innovative healthcare products for mpox is vital for effective management of this public health challenge.
🚀 Understand the market dynamics of Novo Nordisk’s GLP-1 Market Share Decline.
A case of demand underestimation, supply chain strain, and competitor agility. Using systems thinking, we unpack the dynamic forces behind Eli Lilly’s surge—and what strategic levers pharma leaders must pull to stay ahead.
#SyenzaNews #PharmaStrategy #MarketDynamics #NovoNordisk #EliLilly #GLP1
💡 Can tolebrutinib reshape the treatment landscape for progressive multiple sclerosis?
A recent report from the Institute for Clinical and Economic Review reveals promising insights on tolebrutinib, demonstrating a 31% reduction in disability progression for patients with non-relapsing secondary progressive MS. Yet, mixed outcomes and potential safety concerns raise critical questions about its long-term efficacy and market access.
Explore the nuances of this groundbreaking therapy and its implications for healthcare economics.
#SyenzaNews #HealthEconomics #MarketAccess
🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?
This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.
Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!
#SyenzaNews #HealthEconomics #Innovation #MarketAccess
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
